Although the prevalence of pancreatic cancer is increasing, treatment strategies remain limited, and success is rare. A growing body of evidence links pancreatic cancer to pre-existing metabolic disorders, including, but not limited to, type 2 diabetes mellitus and obesity. An infrequently described finding, fatty pancreas, initially described in the context of obesity in the early 20th century, appears to be at the crossroads of type 2 diabetes and obesity on the one hand, and the development of pancreatic cancer on the other. Similarly, other conditions of the pancreas, such as intrapancreatic mucinous neoplasms, also seem to be related to diabetes while increasing the subsequent risk of pancreatic cancer. In this review, the author explores the diagnostic criteria for, and prevalence of, fatty pancreas and the potential link to other pancreatic conditions, including pancreatic cancer. Diagnostic limitations, and areas of controversy are also addressed, as are potential therapeutic approaches to fatty pancreas intended to reduce the subsequent risk of pancreatic cancer.
Get full access to this article
View all access options for this article.
References
1.
BrodyJE. Pancreatic cancer, and why we can't stop it. New York Times, September 24, 2019. 2019: D7.
2.
AggarwalG, KamadaP, ChariST. Prevalence of diabetes mellitus in pancreatic cancer compared to common cancers. Pancreas, 2013; 42:198–201.
3.
EverhartJ, WrightD. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA, 1995; 273:1605–1609.
4.
PannalaR, LeirnessJB, BamletWR, et al.Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology, 2008; 134:981–987.
5.
AndersenD, AndersenDK, KorcM, et al.Diabetes, pancreatogenic diabetes, and pancreatic cancer. Diabetes, 2017; 66:1103–1110.
6.
JarotzkyAJ. [About the changes in the size and structure of the pancreatic cells in some kinds of inanition]. Arch Pathol Anat Physiol Clin Med, 1899; 156:409–450 (Article in German).
7.
LeclercE, VetterSW. The role of S100 proteins and their receptor RAGE in pancreatic cancer. Biochim Biophys Acta, 2015; 1852:2706–2711.
8.
RahnS, ZimmermannV, ViolF, et al.Diabetes as risk factor for pancreatic cancer: Hyperglycemia promotes epithelial-mesenchymal-transition and stem cell properties in pancreatic ductal epithelial cells. Cancer Lett, 2018; 415:129–150.
9.
SchaeferJH. The normal weight of the pancreas in the adult human being: A biometric study. Anat Rec, 1926; 32:119–132.
10.
OgilvieRF. The islands of Langerhans in 19 cases of obesity. J Pathol Bacteriol, 1933; 37:473–481.
11.
OlsenTS. Lipomatosis of the pancreas in autopsy material and its relation to age and overweight. Acta Pathol Microbiol Scand A, 1978; 86A:367–373.
12.
PrachayakulV, AswakulP. Pancreatic steatosis: What should gastroenterologists know? JOP. J Pancreas, 2015; 16:227–231.
13.
ChoiCW, KimGH, KangDH, et al.Associated factors for a hyperechogenic pancreas on endoscopic ultrasound. World J Gastroenterol, 2010; 16:4329–4334.
14.
SepePS, OhriA, SanakaS, et al.A prospective evaluation of fatty pancreas by using EUS. Gastrointest Endosc, 2011; 73:987–993.
15.
SotoudehmaneshR, TahmasbiA, SadeghiA, et al.The prevalence of nonalcoholic fatty pancreas by endoscopic ultrasonography. Pancreas, 2019; 48:1220–1224.
16.
WongVW, WongGL, YeungDK, et al.Fatty pancreas, insulin resistance, and β-cell function: A population study using fat-water magnetic resonance imaging. Am J Gastroenterol, 2014; 109:589–597.
17.
WangD, YuXP, XiaoWM, et al.Prevalence and clinical characteristics of fatty pancreas in Yangzhou, China: A cross-sectional study. Pancreatology, 2018; 18:263–268.
18.
RamkissoonR, GardnerTB. Pancreatic steatosis: An emerging clinical entity. Am J Gastroenterol, 2019; 114:1726–1734.
19.
TroutAT, HunteDE, MouzakiM, et al.Relationship between abdominal fat stores and liver fat, pancreatic fat, and metabolic comorbidities in a pediatric population with non-alcoholic fatty liver disease. Abdom Radiol (NY), 2019; 44:3107–3114.
20.
KhouryT, AsombangAW, BerzinTM, et al.The clinical implications of fatty pancreas: A concise review. Dig Dis Sci, 2017; 62:2658–2667.
21.
SaishoY, ButlerAE, MeierJJ, et al.Pancreas volumes in humans from birth to age one hundred taking into account sex, obesity, and presence of type-2 diabetes. Clin Anat, 2007; 20:933–942.
22.
RossoE, CasnediS, PessauxP, et al.The role of “fatty pancreas” and of BMI in the occurrence of pancreatic fistula after pancreaticoduodenectomy. J Gastrointest Surg, 2009; 13:1845–1851.
23.
TirkesT, JeonCY, LiL, et al.Association of pancreatic steatosis with chronic pancreatitis, obesity, and type 2 diabetes mellitus. Pancreas, 2019; 48:420–426.
24.
SreedharUL, DeSouzaSV, ParkB, et al.A systematic review of intra-pancreatic fat deposition and pancreatic carcinogenesis. J Gastrointest Surg, 2020; 24:2560–2569.
25.
TaylorR. Banting memorial lecture 2012: Reversing the twin cycles of type 2 diabetes. Diabet Med, 2013; 30:267–275.
26.
TaylorR, BarnesAC. Translating aetiological insight into sustainable management of type 2 diabetes. Diabetologia, 2018; 61:273–283.
27.
van GeenenEJ, SmitsMM, SchreuderTC, et al.Nonalcoholic fatty liver disease is related to nonalcoholic fatty pancreas disease. Pancreas, 2010; 39:1185–1190.
28.
van RaalteDH, van der ZijlNJ, DiamantM. Pancreatic steatosis in humans: Cause or marker of lipotoxicity?. Curr Opin Clin Nutr Metab Care, 2010; 13:478–485.
29.
MirrakhimovAE. Nonalcoholic fatty pancreatic disease and cardio-metabolic risk: Is there is a place for obstructive sleep apnea?. Cardiovasc Diabetol, 2014; 13:29.
30.
PatelNS, PetersonMR, BrennerDA, et al.Association between novel MRI-estimated pancreatic fat and liver histology-determined steatosis and fibrosis in non-alcoholic fatty liver disease. Aliment Pharmacol Ther, 2013; 37:630–639.
31.
SzczepaniakLS, VictorRG, MathurR, et al.Pancreatic steatosis and its relationship to β-cell dysfunction in humans: Racial and ethnic variations. Diabetes Care, 2012; 35:2377–2383.
LeeJS, KimSH, JunDW, et al.Clinical implications of fatty pancreas: Correlations between fatty pancreas and metabolic syndrome. World J Gastroenterol, 2009; 15:1869–1875.
34.
SchwenzerNF, MachannJ, MartirosianP, et al.Quantification of pancreatic lipomatosis and liver steatosis by MRI: Comparison of in/opposed-phase and spectral-spatial excitation techniques. Invest Radiol, 2008; 43:330–337.
35.
HeniM, MachannJ, StaigerH, et al.Pancreatic fat is negatively associated with insulin secretion in individuals with impaired fasting glucose and/or impaired glucose tolerance: A nuclear magnetic resonance study. Diabetes Metab Res Rev, 2010; 26:200–205.
36.
PinnickKE, CollinsSC, LondosC, et al.Pancreatic ectopic fat is characterized by adipocyte infiltration and altered lipid composition. Obesity (Silver Spring), 2008; 16:522–530.
37.
GaboritB, AbdesselamI, KoberF, et al.Ectopic fat storage in the pancreas using 1H-MRS: Importance of diabetic status and modulation with bariatric surgery-induced weight loss. Int J Obes (Lond), 2015; 39:480–487.
38.
JonesJS. Adult cystic fibrosis (mucoviscidosis). Fatty replacement of the pancreas in a woman aged 47years. Br J Dis Chest, 1970; 64:25–36.
39.
KurdzielJC, DondelingerR. Fatty infiltration of the pancreas in Shwachman's syndrome: Computed tomography demonstration. Eur J Radiol, 1984; 4:202–204.
40.
LacailleF, ManiTM, BrunelleF, et al.Magnetic resonance imaging for diagnosis of Shwachman's syndrome. J Pediatr Gastroenterol Nutr, 1996; 23:599–603.
41.
JonesNL, HofleyPM, DuriePR. Pathophysiology of the pancreatic defect in Johanson-Blizzard syndrome: A disorder of acinar development. J Pediatr, 1994; 125:406–408.
42.
WaltersMN, LeakPJ, JoskeRA, et al.Murine infection with Reovirus. 3. Pathology of infection with types 1 and 2. Br J Exp Pathol, 1965; 46:200–212.
43.
CatanzaroR, CuffariB, ItaliaA, et al.Exploring the metabolic syndrome: Nonalcoholic fatty pancreas disease. World J Gastroenterol, 2016; 22:7660–7675.
44.
PapakonstantinouO, LadisV, KostaridouS, et al.The pancreas in beta-thalassemia major: MR imaging features and correlation with iron stores and glucose disturbances. Eur Radiol, 2007; 17:1535–1543.
45.
LinWC, ChenJH, LinCH, et al.Rapidly progressive pancreatic lipomatosis in a young adult patient with transfusion-dependent myelodysplastic syndrome. J Formos Med Assoc, 2007; 106:676–679.
46.
ChehterEZ, LongoMA, LaudannaAA, et al.Involvement of the pancreas in AIDS: A prospective study of 109 post-mortems. AIDS, 2000; 14:1879–1886.
47.
DiamondI, VallbonaC. Kwashiorkor in a North American white male. Pediatrics, 1960; 25:248–257.
48.
WengS, ZhouJ, ChenX, SunY, MaoZ, ChaiK. Prevalence and factors associated with nonalcoholic fatty pancreas disease and its severity in China. Medicine (Baltimore), 2018; 97:e11293.
49.
LêKA, VenturaEE, FisherJQ, et al.Ethnic differences in pancreatic fat accumulation and its relationship with other fat depots and inflammatory markers. Diabetes Care, 2011; 34:485–490.
50.
SinghRG, YoonHD, WuLM, et al.Ectopic fat accumulation in the pancreas and its clinical relevance: A systematic review, meta-analysis, and meta-regression. Metabolism, 2017; 69:1–13.
51.
NavinaS, AcharyaC, DeLanyJP, et al.Lipotoxicity causes multisystem organ failure and exacerbates acute pancreatitis in obesity. Sci Transl Med, 2011; 3:107ra110.
52.
MajumderS, PhilipNA, TakahashiN, et al.Fatty pancreas: Should we be concerned?. Pancreas, 2017; 46:1251–1258.
53.
WangCY, OuHY, ChenMF, et al.Enigmatic ectopic fat: Prevalence of nonalcoholic fatty pancreas disease and its associated factors in a Chinese population. J Am Heart Assoc, 2014; 3:e000297.
54.
LiS, SuL, LvG, ZhaoW, et al.Transabdominal ultrasonography of the pancreas is superior to that of the liver for detection of ectopic fat deposits resulting from metabolic syndrome. Medicine (Baltimore), 2017; 96:e8060.
KawadaN, TanakaS. Elastography for the pancreas: Current status and future perspective. World J Gastroenterol, 2016; 22:3712–3724.
57.
KlothC, FabriciusD, WendlikI, et al.Diagnostic accuracy of MRI with MRCP and B-Mode-sonography with elastography of the pancreas in patients with cystic fibrosis: A point-to-point comparison. BMC Res Notes, 2019; 12:150.
58.
SessaF, SolciaE, CapellaC, et al.Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: An investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients. Virchows Arch, 1994; 425:357–367.
59.
MachadoNO, al QadhiH, al WahibiK. Intraductal papillary mucinous neoplasm of pancreas. N Am J Med Sci, 2015; 7:160–175.
60.
StarkA, DonahueTR, ReberHA, et al.Pancreatic cyst disease: A review. JAMA, 2016; 315:1882–1893.
61.
ScheimanJM, HwangJH, MoayyediP. American Gastroenterological Association technical review on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology, 2015; 148:824–848.
62.
Del ChiaoM, VerbekeC, SalviaR, et al.European study group on cystic tumours of the pancreas. European evidence-based guidelines on pancreatic cystic neoplasms. Gut, 2018; 67:789–804.
63.
TanakaM, ChariS, AdsayNV, et al.International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology, 2006; 6:17–32.
64.
TanakaM, Fernández-del CastilloC, AdsayV, et al.International Association of Pancreatology. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology, 2012; 12:183–197.
65.
BerlandLL, SilvermanSG, GoreRM, et al.Managing incidental findings on abdominal CT: White paper of the ACR incidental findings committee. J Am Coll Radiol, 2010; 7:754–773.
66.
MegibowAJ, BakerME, MorganDE, et al.Management of incidental pancreatic cysts: A white paper of the ACR incidental findings committee. J Am Coll Radiol, 2017; 14:911–923.
67.
NakamuraM, MiyasakaY, SadakariY, et al.Comparison of guidelines for intraductal papillary mucinous neoplasm: What is the next step beyond the current guidelines?. Ann Gastroenterol Surg, 2017; 1:90–98.
68.
XuMM, YinS, SiddiquiAA, et al.Comparison of the diagnostic accuracy of three current guidelines for the evaluation of asymptomatic pancreatic cystic neoplasms. Medicine (Baltimore), 2017; 96:e7900.
69.
PushalkarS, HundeyinM, DaleyD, et al.The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov, 2018; 8:403–416.
70.
AykutB, PushalkarS, ChenR, et al.The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL. Nature, 2019; 574:264–267.
71.
FarrellJJ, ZhangL, ZhouH, et al.Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. Gut, 2012; 61:582–588.
72.
SongF, Hurtado del PozoC, RosarioR, et al.RAGE regulates the metabolic and inflammatory response to high-fat feeding in mice. Diabetes, 2014; 63:1948–1965.
73.
VongsuvanhR, GeorgeJ, QiaoL, et al.Visceral adiposity in gastrointestinal and hepatic carcinogenesis. Cancer Lett, 2013; 330:1–10.
74.
HertzerKM, XuM, MoroA, et al.Robust early inflammation of the peripancreatic visceral adipose tissue during diet-induced obesity in the KrasG12D model of pancreatic cancer. Pancreas, 2016; 45:458–465.
75.
DawsonDW, HertzerK, MoroA, et al.High-fat, high-calorie diet promotes early pancreatic neoplasia in the conditional KrasG12D mouse model. Cancer Prev Res (Phila), 2013; 6:1064–1073.
76.
ChangHH, EiblG. Obesity-induced adipose tissue inflammation as a strong promotional factor for pancreatic ductal adenocarcinoma. Cells, 2019; 8:pii:E673.
77.
MizunoS, NakaiY, IsayamaH, et al.Visceral adiposity and high adiponectin levels are associated with the prevalence of pancreatic cystic lesions. Int J Obes (Lond), 2019; 43:169–175.
78.
HonkaH, KoffertJ, HannukainenJC, et al.The effects of bariatric surgery on pancreatic lipid metabolism and blood flow. J Clin Endocrinol Metab, 2015; 100:2015–2023.
79.
HeiskanenMA, MotianiKK, MariA, et al.Exercise training decreases pancreatic fat content and improves beta cell function regardless of baseline glucose tolerance: A randomised controlled trial. Diabetologia, 2018; 61:1817–1828.
80.
BosettiC, RosatoV, LiD, et al.Diabetes, antidiabetic medications, and pancreatic cancer risk: An analysis from the International Pancreatic Cancer Case-Control Consortium. Ann Oncol, 2014; 25:2065–2072.
81.
ZhouPT, LiB, LiuFR, et al.Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: A systematic review and meta-analysis. Oncotarget, 2017; 8:25242–25250.
82.
WangZ, LaiST, XieL, et al.Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Res Clin Pract, 2014; 106:19–26.
83.
YinM, ZhouJ, GorakEJ, et al.Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: A systematic review and meta-analysis. Oncologist, 2013; 18:1248–1255.
84.
QianW, LiJ, ChenK, et al.Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer. Life Sci, 2018; 208:253–261.
85.
ZechnerD, BürtinF, AlbertAC, et al.Intratumoral heterogeneity of the therapeutical response to gemcitabine and metformin. Oncotarget, 2016; 7:56395–56407.
86.
ElashoffM, MatveyenkoAV, GierB, et al.Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology, 2011; 141:150–156.
87.
El AzizMSA, CahyadiO, MeierJJ, et al.Incretin-based glucose-lowering medications and the risk for acute pancreatitis and malignancies—a meta-analysis based on cardiovascular outcomes trials. Diabetes Obes Metab, 2020; 22:699–704.
88.
PintoLC, FalcettaMR, RadosDV, et al.Glucagon-like peptide-1 receptor agonists and pancreatic cancer: A meta-analysis with trial sequential analysis. Sci Rep, 2019; 9:2375.
89.
MonamiM, NreuB, ScatenaA, et al.Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials. Diabetes Obes Metab, 2017; 19:1233–1241.
90.
Souza-MelloV, GregórioBM, Relvas-LucasB, et al.Pancreatic ultrastructural enhancement due to telmisartan plus sitagliptin treatment in diet-induced obese C57BL/6 mice. Pancreas, 2011; 40:715–722.
91.
JiaDM, OtsukiM. Troglitazone stimulates pancreatic growth in normal rats. Pancreas, 2002; 24:303–312.
92.
ZhaoL, JiangSJ, LuFE, et al.Effects of berberine and cinnamic acid on palmitic acid-induced intracellular triglyceride accumulation in NIT-1 pancreatic β cells. Chin J Integr Med, 2016; 22:496–502.
